Industry Sponsored Satellite Symposia ISAL XVI 2017
(Companies in alphabetical order)
Amgen GmbH (Gold Circle Member)
Satellite Symposium II: Sunday, February 19, 2017: 18.15 -19.15 (Lecture Hall III/IV)
„Novel Treatment Strategies in Acute Leukemias: The Evolving Role of Immunotherapy“
18.15-18.45
M. Subklewe, Munich, DE
CE33 BiTE
18.45-19.15
N. Gökbuget, Frankfurt, DE
CD19 BiTE in ALL
Remarks and Conclusion
Celgene GmbH (Gold Circle Member)
Satellite Symposium VI: Tuesday, February 21, 2017: 16.30 – 17.30 (Lecture Hall III/IV)
„Upcoming Frontiers in the Treatment of AML“
Chair:
W. Hiddemann, Munich, DE
Opening:
W. Hiddemann, Munich, DE
16.35-17.00
Groenbeck, K., Copenhagen, DK
A Rationale for Combining DNA Hypomethylators with Checkpoint Inhibitors in Myeloid Malignancies
17.00-17.25
Thol, F., Hannover, DE
Key Epidemiological and Clinical Findings in AML Patients with IDH Mutations
Remarks and Conclusion
Immune Pharmaceuticals (Gold Circle Member)
Satellite Symposium III: Monday, February 20, 2017: 12.45 – 13.45 (Lecture Hall III/IV)
„Reinforcing the Efficacy of Immunotherapy for the Maintenance of remission in AML with Ceplene“
Chair:
W. Hiddemann, Munich, DE
Opening Remarks:
W. Hiddemann, Munich, DE
12.50-13.10
K. Hellstrand, Gothenburg, SE
Role of Cytotoxic T Cells in Remission Maintenance with Ceplene/IL-2 Therapy in AML
13.10-13.15
Discussion
13.15-13.40
Rowe, J., Jerusalem, IL
Maintenance Therapy in AML
13.40-13.45
Discussion
Janssen Pharmaceutica NV (Gold Circle Member)
Satellite Symposium V: Monday, February 20, 2017: 18.15 – 19.15 (Lecture Hall III/IV)
„Raising the Bar in AML: Novel Endpoints and New Treatment Approaches“
Chair:
W. Hiddemann, Munich, DE
Learning Objectives:
After participating in this Symposium you should be able to:
- Explain the Importance of MRD Assessment in AML Clinical Trials in improving Patient Outcomes
- Describe the Main Immunotherapy Targets in AML and the Rationale for the Use of these Agents
18.15 Introduction
W. Hiddemann, Munich, DE
18.25
G. Ossenkoppele, Amsterdam, NL
Utility of MRD Assessment in AML
18.40 Panel Discussion
18.55
G. Roboz, New York, NY, USA
Future Treatment Options for Patients with AML: A Focus on Immunotherapy
19.05 Panel Discussion
Jazz Pharmaceuticals Germany GmbH (Gold Circle Member)
Satellite Symposium VII: Tuesday, February 21, 2017: 17.45 – 18.45 (Lecture Hall III/IV)
„New Perspectives in AML“
Chair:
W. Hiddemann, Munich, DE
Introduction:
W. Hiddemann, Munich, DE
17.50-18.10
U. Krug, Leverkusen, DE
How can we Optimize 7+3?
18.10-18.30
H. Kantarjian, Houston, TX , USA
How can we Expand 7+3?
18.30-18.45
Summary and Final Discussion
W. Hiddemann, Munich, DE
SHIRE GmbH (Gold Circle Member)
Satellite Symposium I: Sunday, February 19, 2017: 17.00 – 18.00 (Lecture Hall III/IV)
„Rare Diseases in Hematology“
Chair:
W. Hiddemann, Munich, DE
17.00-17.20
M. Griesshammer, Minden, DE
Therapeutic Options of Essential Thrombocythemia and Perspectives
17.20-17.40
A. Zimran, Jerusalem, IL
Why Hematologists Should Care about Gaucher Disease
17.40-18.00
N. Gökbuget, Frankfurt, DE
Experience with PEG-Asparaginase in Adult ALL
Remarks and Conclusion
TEVA GmbH (Gold Circle Member)
Satellite Symposium IV: Monday, February 20, 2017: 16.30 – 18.00 (Lecture Hall III/IV)
„Diagnosis and Management of APL: Teva Young Hematologists Award“
Co-Chairs:
P. Fenaux, Bobigny, F
R.F. Schlenk, Heidelberg, DE
16:30–16:35
Welcome and Introduction
Chair: Pierre Fenaux, France
16:35–16:50
APL: From Worst Prognosis to Best Outcome
Pierre Fenaux, France
16:50–17:05
Best Abstract Presentation 1
(Includes 3 minutes for Q&A)
17:05–17:20
Best Abstract Presentation 2
(Includes 3 minutes for Q&A)
17:20–17:35
Best Abstract Presentation 3
(Includes 3 minutes for Q&A)
17:35–17:50
Best Abstract Presentation 4
(Includes 3 minutes for Q&A)
17:50–18:00
Conclusions
Chair: Richard Schlenk, Germany